BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders.

Elliot HampseyAdam PerkinsAllan H Young

Published in: Expert opinion on investigational drugs (2023)

: There is a relative paucity of data regarding BNC210, albeit the small amount of mostly non-peer reviewed data indicate it is a well-tolerated, effective anxiolytic. Phase III trials are required for proper appraisal of its utility.

Keyphrases

phase iii
electronic health record
open label
phase ii
clinical trial
big data
double blind
machine learning
placebo controlled
data analysis
combination therapy
study protocol